Clinical Policy: Carfilzomib (Kyprolis)

Reference Number: LA.PHAR.309
Effective Date: 02.03.24
Last Review Date: ~~06.15.23~~05.07.24 Coding Implications
Line of Business: Medicaid Revision Log

See Important Reminder at the end of this policy for important regulatory and legal information.

Please note: This policy is for medical benefit

Description
Carfilzomib (Kyprolis®) is a proteasome inhibitor.

FDA Approved Indication(s)
Kyprolis is indicated

- For the treatment of adult patients with relapsed or refractory multiple myeloma (MM) who have received one to three lines of therapy in combination with:
  - Lenalidomide and dexamethasone or
  - Dexamethasone or
  - Daratumumab and dexamethasone or
  - Daratumumab and hyaluronidase-fihj and dexamethasone or
  - Isatuximab and dexamethasone
- As a single agent for the treatment of adult patients with relapsed or refractory MM who have received one or more lines of therapy.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of Louisiana Healthcare Connections that Kyprolis is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Multiple Myeloma (must meet all)**:**

1. Diagnosis of MM;
2. Prescribed by or in consultation with an oncologist;
3. Age ≥ 18 years;
4. For primary therapy, Kyprolis is prescribed in one of the following ways (a, b, or c):*
   a. In combination with dexamethasone and lenalidomide;
   b. In combination with dexamethasone and cyclophosphamide;
   c. In combination with dexamethasone, lenalidomide, and Darzalex® (daratumumab);

   **Prior authorization may be required.*
5. For maintenance therapy, Kyprolis is prescribed in combination with lenalidomide;

~~5.~~6. For previously treated multiple myeloma for relapsed or refractory disease, Kyprolis is prescribed in one of the following ways (a - ~~g~~h):*
   a. In combination with dexamethasone or with lenalidomide plus dexamethasone in patients who have received one or three lines of therapy *(see Appendix B for examples of prior therapy)*;
   b. As a single agent in patients who have received one or more lines of therapy;
   c. In combination with Darzalex® (daratumumab) or Darzalex Faspro™ (daratumumab/hyaluronidase-fihj) and dexamethasone in patients who have received one or three lines of therapy;
   d. In combination with Sarclisa (isatuximab-irfc) and dexamethasone in patients who have received one or three lines of therapy;
   e. In combination with Xpovio (Selinexor) and dexamethasone for relapse or progressive disease;
   f. In combination with dexamethasone and cyclophosphamide, with or without thalidomide, for relapse or progressive disease;
   g. In combination with pomalidomide and dexamethasone for patients who have received at least two prior therapies, including an immunomodulatory agent and a proteasome inhibitor and who have demonstrated disease progression on or within 60 days of completion of the last therapy;
   h. In combination with bendamustine and dexamethasone for patients with late relapse or progressive disease who have failed at least three prior therapies;

   **Prior authorization may be required.*

~~6.~~7. Request meets one of the following (a, b, c, d, or e):*
   a. Monotherapy: dose does not exceed 56 mg/m^2 twice weekly each 28-day cycle;
   b. With dexamethasone and lenalidomide: dose does not exceed 27 mg/m^2 twice weekly 3 out of 4 weeks for twelve 28-day cycles, then 27 mg/m^2 twice weekly 2 out of 4 weeks for the next six 28-day cycles for up to a total of 18 cycles;
   c. With dexamethasone ± Darzalex: dose does not exceed (i or ii):
      i. 70 mg/m^2 once weekly each 28-day cycle;
      ii. 56 mg/m^2 twice weekly each 28-day cycle;
   d. With dexamethasone and Sarclisa: 56 mg/m^2 twice weekly each 28-day cycle;
   e. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

   **Prescribed regimen must be FDA-approved or recommended by NCCN.*

Approval duration: 6 months

B. Waldenstrom's Macroglobulinemia (Lymphoplasmacytic Lymphoma) (off-label) (must meet all)**:**
1. Diagnosis of Waldenstrom's macroglobulinemia (i.e., lymphoplasmacytic lymphoma) (WM/LPL);
2. Prescribed by or in consultation with an oncologist;
3. Age ≥ 18 years;
4. Prescribed as a component of CaRD (carfilzomib, rituximab*, and dexamethasone) regimen as primary or Kyprolis-relapsed therapy;

   **Prior authorization may be required.*
5. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).*

**Prescribed regimen must be FDA-approved or recommended by NCCN.*

Approval duration: 6 months

C. Systemic Light Chain Amyloidosis (off-label) (must meet all)**:**
1. Diagnosis of Systemic Light Chain Amyloidosis;
2. Prescribed by or in consultation with an oncologist;
3. Age ≥ 18 years;
4. Request is for relapsed/refractory non-cardiac disease;
5. Prescribed in one of the following ways (a or b):
   a. As a single agent;
   b. In combination with dexamethasone;
6. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).*

**Prescribed regimen must be FDA-approved or recommended by NCCN.*

Approval duration: 6 months

D. Other diagnoses/indications (must meet 1 or 2)**:**
1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: LA.PMN.53 for Medicaid.

II. Continued Therapy

A. Multiple Myeloma (must meet all)**:**
1. Currently receiving medication via Louisiana Healthcare Connections benefit, or documentation supports that member is currently receiving Kyprolis for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. If request is for a dose increase, request meets one of the following (a, b, c, d, or e):*
   a. Monotherapy: new dose does not exceed 56 mg/m^2 twice weekly each 28-day cycle;
   b. With dexamethasone and lenalidomide: new dose does not exceed 27 mg/m^2 twice weekly 3 out of 4 weeks for twelve 28-day cycles, then 27 mg/m^2 twice weekly 2 out of 4 weeks for the next six 28-day cycles for up to a total of 18 cycles;
   c. With dexamethasone ± Darzalex: new does not exceed (i or ii):
      i. 70 mg/m^2 once weekly each 28-day cycle;
      ii. 56 mg/m^2 twice weekly each 28-day cycle;
   d. With dexamethasone and Sarclisa: 56 mg/m^2 twice weekly each 28-day cycle;
   e. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

**Prescribed regimen must be FDA-approved or recommended by NCCN.*

Approval duration: 12 months

B. Waldenstrom's Macroglobulinemia (Lymphoplasmacytic Lymphoma) (off-label) (must meet all)**:**
1. Currently receiving medication via Louisiana Healthcare Connections benefit, or documentation supports that member is currently receiving Kyprolis for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).*

**Prescribed regimen must be FDA-approved or recommended by NCCN.*

Approval duration: 12 months

C. Systemic Light Chain Amyloidosis (off-label) (must meet all)**:**
1. Currently receiving medication via Louisiana Healthcare Connections benefit, or documentation supports that member is currently receiving Kyprolis for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).*

**Prescribed regimen must be FDA-approved or recommended by NCCN.*

Approval duration: 12 months

D. Other diagnoses/indications (must meet 1 or 2)**:**
1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: LA.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – LA.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

CaRD: carfilzomib, rituximab, dexamethasone
FDA: Food and Drug Administration
MM: multiple myeloma
NCCN: National Comprehensive Cancer Network
WM/LPL: Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Formatted: Don't keep with next

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Kyprolis (carfilzomib), bortezomib (Velcade®), lenalidomide (Revlimid), cyclophosphamide, dexamethasone	MM: Examples of primary therapy • Bortezomib/dexamethasone • Bortezomib/lenalidomide/dexamethasone • Bortezomib/cyclophosphamide/dexamethasone • ~~Carfilzomib~~Bortezomib/doxorubicin/dexamethasone • Bortezomib/thalidomide/dexamethasone • Carfilzomib/cyclophosphamide/dexamethasone • Carfilzomib/lenalidomide/dexamethasone • Cyclophosphamide/lenalidomide/dexamethasone • Daratumumab/lenalidomide/dexamethasone • Daratumumab/lenalidomide/bortezomib/ dexamethasone • Daratumumab/carfilzomib/lenalidomide/ dexamethasone • Daratumumab/cyclophosphamide/bortezomib/ dexamethasone • Daratumumab/bortezomib/thalidomide/ dexamethasone • Daratumumab/bortezomib/melphalan/prednisone • Dexamethasone/thalidomide/cisplatin/doxorubicin/ cyclophosphamide/etoposide/bortezomib (VTD-PACE) • Ixazomib/cyclophosphamide/dexamethasone • Ixazomib/lenalidomide/dexamethasone • ~~Lenalidomide/low-dose dexamethasone~~~~Carfilzomib/cyclophosphamide/dexamethasone~~ • ~~Carfilzomib/lenalidomide/dexamethasone~~ •	Varies
Kyprolis (carfilzomib), bortezomib (Velcade), lenalidomide (Revlimid), Darzalex® (daratumumab), Ninlaro® (ixazomib), Pomalyst (pomalidomide), Empliciti® (elotuzumab), ~~Farydak (panobinostat),~~	MM: Examples of therapy for previously treated for relapsed or refractory disease: • Bendamustine • Bendamustine/bortezomib/dexamethasone • Bendamustine/lenalidomide/dexamethasone • Bendamustine/carfilzomib/dexamethasone • Bortezomib/dexamethasone • ~~Carfilzomib~~Bortezomib/lenalidomide/dexamethasone • Bortezomib/liposomal doxorubicin/dexamethasone • Bortezomib/cyclophosphamide/dexamethasone • Carfilzomib/cyclophosphamide/dexamethasone • Carfilzomib/dexamethasone • Carfilzomib/lenalidomide/dexamethasone • Carfilzomib/cyclophosphamide/dexamethasone • Carfilzomib/cyclophosphamide/thalidomide/ dexamethasone • Cyclophosphamide/lenalidomide/dexamethasone	Varies

Formatted Table

Formatted: List Paragraph, Indent: Left: -0.01", Hanging: 0.16", Bulleted + Level: 1 + Aligned at: 0.25" + Indent at: 0.5", Position: Horizontal: 0.25", Relative to: Column, Vertical: 0", Relative to: Paragraph, Horizontal: 0.13", Wrap Around

Thalomid® (thalidomide), bendamustine, cyclophosphamide, dexamethasone, Sarclisa® (istatuximab-irfc), Xpovio® (selinexor)	• Cyclophosphamide • Daratumumab • Daratumumab/bortezomib/dexamethasone • Daratumumab/carfilzomib/dexamethasone • ~~Daratumumab/lenalidomide/dexamethasone~~ • ~~Ixazomib/lenalidomide/dexamethasone~~ • ~~Pomalidomide~~cyclophosphamide/bortezomib/ dexamethasone • Daratumumab/lenalidomide/dexamethasone • Daratumumab/pomalidomide/dexamethasone • Dexamethasone/cyclophosphamide/etoposide/cisplatin • Dexamethasone/thalidomide/cisplatin/doxorubicin/ cyclophosphamide/etoposide/ +/- bortezomib • Elotuzumab/lenalidomide/dexamethasone • ~~Panobinostat~~Elotuzumab/bortezomib/dexamethasone • ~~Carfilzomib~~Elotuzumab/pomalidomide/dexamethasone • Istatuximab-irfc/carfilzomib/dexamethasone • Ixazomib/cyclophosphamide/dexamethasone • ~~Carfilzomib~~Ixazomib/lenalidomide/dexamethasone • Ixazomib/pomalidomide/desamethasone • Isatuximab-irfc/pomalidomide/dexamethasone • Lenalidomide/dexamethasone Pomalidomide/bortezomib/dexamethasone • Pomalidomide/carfilzomib/dexamethasone • ~~Carfilzomib~~Pomalidomide/cyclophosphamide/~~thalidomide/~~dexamethasone • Pomalidomide/dexamethasone • Selinexor/bortezomib/dexamethasone • Selinexor/carfilzomib/dexamethasone • Selinexor/daratumumab/dexamethasone • Selinexor/opomalidomide/dexamthasone • Venetoclax/dexamethasone • Ideocabtagene vicleucel • Ciltacabtagene autoleucel • Teclistamab-cqyv • Benlantamab mafodotin-blmf	
rituximab (Rituxan®), Kyprolis (carfilzomib) dexamethasone	WM/LPL: CaRD (carfilzomib, rituximab, and dexamethasone)	Varies

Formatted: List Paragraph, Indent: Left: -0.01", Hanging: 0.16", Bulleted + Level: 1 + Aligned at: 0.25" + Indent at: 0.5", Position: Horizontal: 0.25", Relative to: Column, Vertical: 0", Relative to: Paragraph, Horizontal: 0.13", Wrap Around

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/Black Box Warnings

None reported

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
MM	Kyprolis + Dexamethasone: • Cycles: Kyprolis IV as a 30-minute infusion (28-day cycles). o Cycle 1: administer Kyprolis 20 mg/m^2 on Day 1 and 70 mg/m^2 on Days 8 and 15 o Cycle 2 and later: 70 mg/m^2 on Day 1, 8, and 15 • Dose (once weekly 20/70 mg/m^2 regimen): o Starting dose of Kyprolis 20 mg/m^2 on Cycle 1, Day 1 o If tolerated, escalate Kyprolis to 70 mg/m^2 on Day 8 of Cycle 1. o Dexamethasone: 40 mg PO or IV on Days 1, 8, 15 of all 28-day cycles and on Day 22 of Cycles 1-9. Kyprolis + Dexamethasone, OR **Monotherapy**: • Cycles: Kyprolis IV as a 30-minute infusion (28-day cycles). o Cycle 1: administer Kyprolis 20 mg/m^2 on Days 1 and 2, and 56 mg/m^2 on Day 8, 9, 15, and 16 o Cycle 2 and later: administer Kyprolis 56 mg/m^2 on Days 1, 2, 8, 9, 15 and 16 o For monotherapy: Cycle 13 and later: administer Kyprolis 56 mg/m^2 on Days 1, 2, 15 and 16 • Dose (twice weekly 20/56 mg/m^2 regimen): o Starting dose of Kyprolis 20 mg/m^2 on Cycle 1, Days 1 and 2 o If tolerated, escalate Kyprolis to 56 mg/m^2 on Day 8 of Cycle 1. *Do not include if Monotherapy:* o Dexamethasone: 20 mg PO or IV on Days 1, 2, 8, 9, 15, 16, 22 and 23 of each 28-day cycle. Kyprolis + lenalidomide + Dexamethasone, OR **Monotherapy**: • Cycles: Kyprolis IV as a 10-minute infusion for 28-day cycles. o Cycle 1: administer Kyprolis 20 mg/m^2 on Days 1 and 2, and 27 mg/m^2 on Days 8, 9, 15 and 16 o Cycle 2 to 12: administer Kyprolis 27 mg/m^2 on Days 1, 2, 8, 9, 15 and 16 o Cycle 13 and later, administer Kyprolis 27mg/m^2 on Day 1, 2, 15 and 16	70 mg/m^2

Formatted Table

Indication	Dosing Regimen	Maximum Dose
	o Discontinue Kyprolis after Cycle 18 and continue lenalidomide and dexamethasone thereafter. • Dose (twice weekly 20/27 mg/m^2 regimen): o Starting dose of Kyprolis: 20 mg/m^2 on Cycle 1, Days 1 and 2 o If tolerated, escalate Kyprolis to 27 mg/m^2 on Day 8 of Cycle 1. *Do not include if Monotherapy:* o Lenalidomide: 25 mg PO QD on Days 1–21 of each cycle. o Dexamethasone: 40 mg PO or IV on Days 1, 8, 15, and 22 of each 28-day cycle. Kyprolis + Darzalex + Dexamethasone: Twice weekly 20/56 mg/m^2 regimen: • Cycles: Kyprolis IV as a 30-minute infusion (28-day cycles). o Cycle 1: administer Kyprolis 20 mg/m^2 on Days 1 and 2 and 56 mg/m^2 on Days 8, 9, 15 and 16 o Cycle 2 and later: administer Kyprolis 56 mg/m^2 on Days 1, 2, 8, 9, 15 and 16 • Dose: o Starting dose of Kyprolis: 20 mg/m^2 on Cycle 1, Days 1 and 2 o If tolerated, escalate Kyprolis to 56 mg/m^2 on Day 8 of Cycle 1 o See prescribing information for Darzalex, Darzalex Faspro, and dexamethasone dosing. Once weekly 20/70 mg/m^2 regimen: • Cycles: Kyprolis IV as a 30-minute infusion (28-day cycles). o Cycle 1: administer Kyprolis 20 mg/m^2 on Day 1 and 70 mg/m^2 on Days 8 and 15 o Cycle 2 and later: administer Kyprolis 70 mg/m^2 on Days 1, 8 and 15 • Dose: o Starting dose of Kyprolis: 20 mg/m^2 on Cycle 1, Days 1 and 2 o If tolerated, escalate Kyprolis to 70 mg/m^2 on Day 8 of Cycle 1 o See prescribing information for Darzalex, Darzalex Faspro, and dexamethasone dosing. Kyprolis + Sarclisa + Dexamethasone:	

Formatted Table

Indication	Dosing Regimen	Maximum Dose
	Twice weekly 20/56 mg/m^2 regimen: • Cycles: Kyprolis IV as a 30-minute infusion (28-day cycles). o Cycle 1: administer Kyprolis 20 mg/m^2 on Days 1 and 2 and 56 mg/m^2 on Days 8, 9, 15 and 16 o Cycle 2 and later: administer Kyprolis 56 mg/m^2 on Days 1, 2, 8, 9, 15 and 16 • Dose: o Starting dose of Kyprolis: 20 mg/m^2 on Cycle 1, Days 1 and 2 o If tolerated, escalate Kyprolis to 56 mg/m^2 on Day 8 of Cycle 1 o See prescribing information for Sarclisa dosing. _____ *Calculate the Kyprolis dose using the patient's actual body surface area at baseline. In patients with a body surface area greater than 2.2 m^2, calculate the dose based upon a body surface area of 2.2 m^2.*	

Formatted Table

VI. Product Availability

Formatted: Keep with next

Single-dose vial: 10 mg, 30 mg, 60 mg

VII. References

1. Kyprolis Prescribing Information. Thousand Oaks: Onyx Pharmaceuticals, Inc.; June 2022. Available at: ~~http~~https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/Kyprolis/kyprolis~~.com~~_pi.pdf. Accessed ~~July 12, 2022~~August 6, 2023.
2. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at: http://www.nccn.org/professionals/drug_compendium. Accessed ~~July 12, 2022~~August 6, 2023.
3. National Comprehensive Cancer Network. Multiple Myeloma Version ~~05.2022.~~03.2023 Available at: https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf. Accessed ~~July 12, 2022~~August 6, 2023.
4. National Comprehensive Cancer Network. Waldenstrom's macroglobulinemia-lymphoplasmacytic lymphoma Version 01.2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/waldenstroms.pdf. Accessed ~~July 12, 2022~~August 6, 2023.
5. National Comprehensive Cancer Network. Systemic Light Chain Amyloidosis Version ~~1.2022~~2.2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/amyloidosis.pdf. Accessed ~~July 12, 2022~~August 6, 2023.

Formatted: Don't keep lines together

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J9047	Injection, carfilzomib, 1 mg

Reviews, Revisions, and Approvals	Date	LDH Approval Date
Converted corporate to local policy.	06.15.23	01.03.24
Annual review: updated MM initial approval criteria to include "for maintenance therapy, Kyprolis is prescribed in combination with lenalidomide" and "in combination with bendamustine and dexamethasone for patients with late relapse or progressive disease who have failed at least three prior therapies" to align with current NCCN compendium and MM guidelines; for Appendix B, updated section with current MM primary therapies and previously treated for relapsed or refractory therapies per current MM guidelines version 3.2023 and removed Panobinostat regimens as agent was withdrawn from market; references reviewed and updated.	05.07.24	

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.